These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 18559840)
61. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068 [TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690 [TBL] [Abstract][Full Text] [Related]
64. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604 [TBL] [Abstract][Full Text] [Related]
65. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore. Nguyen HV; Tan GS; Tapp RJ; Mital S; Ting DS; Wong HT; Tan CS; Laude A; Tai ES; Tan NC; Finkelstein EA; Wong TY; Lamoureux EL Ophthalmology; 2016 Dec; 123(12):2571-2580. PubMed ID: 27726962 [TBL] [Abstract][Full Text] [Related]
66. Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom. Long EF; Mandalia R; Mandalia S; Alistar SS; Beck EJ; Brandeau ML PLoS One; 2014; 9(4):e95735. PubMed ID: 24763373 [TBL] [Abstract][Full Text] [Related]
67. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Farnham PG; Sansom SL; Hutchinson AB Med Decis Making; 2012; 32(3):459-69. PubMed ID: 22247422 [TBL] [Abstract][Full Text] [Related]
68. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465 [TBL] [Abstract][Full Text] [Related]
69. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Kim JJ; Ortendahl J; Goldie SJ Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455 [TBL] [Abstract][Full Text] [Related]
70. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570 [TBL] [Abstract][Full Text] [Related]
71. Who should be screened for HIV infection? A cost-effectiveness analysis. McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077 [TBL] [Abstract][Full Text] [Related]
72. Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation. Thompson SG; Bown MJ; Glover MJ; Jones E; Masconi KL; Michaels JA; Powell JT; Ulug P; Sweeting MJ Health Technol Assess; 2018 Aug; 22(43):1-142. PubMed ID: 30132754 [TBL] [Abstract][Full Text] [Related]
73. Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis. Scott RK; Crochet S; Huang CC Infect Dis Obstet Gynecol; 2018; 2018():6024698. PubMed ID: 29731602 [TBL] [Abstract][Full Text] [Related]
74. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. Vijan S; Hofer TP; Hayward RA JAMA; 2000 Feb; 283(7):889-96. PubMed ID: 10685713 [TBL] [Abstract][Full Text] [Related]
75. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317 [TBL] [Abstract][Full Text] [Related]
76. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061 [TBL] [Abstract][Full Text] [Related]
77. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. Danese MD; Powe NR; Sawin CT; Ladenson PW JAMA; 1996 Jul 24-31; 276(4):285-92. PubMed ID: 8656540 [TBL] [Abstract][Full Text] [Related]
78. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Walensky RP; Weinstein MC; Kimmel AD; Seage GR; Losina E; Sax PE; Zhang H; Smith HE; Freedberg KA; Paltiel AD Am J Med; 2005 Mar; 118(3):292-300. PubMed ID: 15745728 [TBL] [Abstract][Full Text] [Related]
79. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877 [TBL] [Abstract][Full Text] [Related]
80. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]